These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

253 related items for PubMed ID: 19395027

  • 1. Correlation between trough imatinib plasma concentration and clinical response in chronic myeloid leukemia.
    Mahon FX, Molimard M.
    Leuk Res; 2009 Aug; 33(8):1147-8; author reply 1149-50. PubMed ID: 19395027
    [No Abstract] [Full Text] [Related]

  • 2. Cytogenetic and molecular responses to standard-dose imatinib in chronic myeloid leukemia are correlated with Sokal risk scores and duration of therapy but not trough imatinib plasma levels.
    Forrest DL, Trainor S, Brinkman RR, Barnett MJ, Hogge DE, Nevill TJ, Shepherd JD, Nantel SH, Toze CL, Sutherland HJ, Song KW, Lavoie JC, Power MM, Abou-Mourad Y, Smith CA.
    Leuk Res; 2009 Feb; 33(2):271-5. PubMed ID: 18762338
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Pharmacokinetics and pharmacodynamics of imatinib in a phase I trial with chronic myeloid leukemia patients.
    Peng B, Hayes M, Resta D, Racine-Poon A, Druker BJ, Talpaz M, Sawyers CL, Rosamilia M, Ford J, Lloyd P, Capdeville R.
    J Clin Oncol; 2004 Mar 01; 22(5):935-42. PubMed ID: 14990650
    [Abstract] [Full Text] [Related]

  • 11. Relationship of serum imatinib trough level and response in CML patients: long term follow-up.
    Awidi A, Ayed AO, Bsoul N, Magablah A, Mefleh R, Dweiri M, Ramahi M, Arafat E, Bishtawi M, Marie L.
    Leuk Res; 2010 Dec 01; 34(12):1573-5. PubMed ID: 20688395
    [Abstract] [Full Text] [Related]

  • 12. [Molecular relapse of chronic myeloid leukemia after discontinuation of imatinib mesylate for maintaining complete molecular response for more than 2 years].
    Kiguchi T, Tauchi T, Ohyashiki K.
    Rinsho Ketsueki; 2009 Jan 01; 50(1):52-4. PubMed ID: 19225231
    [Abstract] [Full Text] [Related]

  • 13. Peripheral blood monitoring of chronic myeloid leukemia during treatment with imatinib, second-line agents, and beyond.
    Lima L, Bernal-Mizrachi L, Saxe D, Mann KP, Tighiouart M, Arellano M, Heffner L, McLemore M, Langston A, Winton E, Khoury HJ.
    Cancer; 2011 Mar 15; 117(6):1245-52. PubMed ID: 21381013
    [Abstract] [Full Text] [Related]

  • 14. Clinical pharmacokinetics of imatinib mesylate.
    Levêque D, Maloisel F.
    In Vivo; 2005 Mar 15; 19(1):77-84. PubMed ID: 15796158
    [Abstract] [Full Text] [Related]

  • 15. Insufficient outcomes with imatinib mesylate: case report of Ph-positive acute myeloid leukemia evolving from myelodysplastic syndrome.
    Isoda A, Nakahashi H, Hoshino T, Mitsui T, Yoshida Y.
    Am J Hematol; 2007 Jun 15; 82(6):501-2. PubMed ID: 17301971
    [No Abstract] [Full Text] [Related]

  • 16. Imatinib dose escalation in 74 failure or suboptimal response chronic myeloid leukaemia patients at 3-year follow-up.
    Breccia M, Stagno F, Vigneri P, Latagliata R, Cannella L, Del Fabro V, Di Raimondo F, Alimena G.
    Am J Hematol; 2010 May 15; 85(5):375-7. PubMed ID: 20306543
    [No Abstract] [Full Text] [Related]

  • 17. [Trends in molecular targeting therapeutics for chronic myeloid leukemia].
    Nagai T.
    Rinsho Ketsueki; 2007 Oct 15; 48(10):1360-9. PubMed ID: 17933121
    [No Abstract] [Full Text] [Related]

  • 18. Gleevec: zeroing in on cancer.
    Capriotti T.
    Medsurg Nurs; 2002 Dec 15; 11(6):301-4. PubMed ID: 12520979
    [No Abstract] [Full Text] [Related]

  • 19. Specific assessment of BCR-ABL transcript overexpression and imatinib resistance in chronic myeloid leukemia patients.
    Bianchini M, De Brasi C, Gargallo P, Gonzalez M, Bengió R, Larripa I.
    Eur J Haematol; 2009 Apr 15; 82(4):292-300. PubMed ID: 19191867
    [Abstract] [Full Text] [Related]

  • 20. Imatinib trough plasma levels do not correlate with the response to therapy in patients with chronic myeloid leukemia in routine clinical setting.
    Faber E, Friedecký D, Mičová K, Rožmanová S, Divoká M, Jarošová M, Indrák K, Adam T.
    Ann Hematol; 2012 Jun 15; 91(6):923-9. PubMed ID: 22231281
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 13.